ARK Genomic Revolution ETF ARKG
Set alert
48.29 USD -3.11 -6.05%
At close · Nov 2
48.55 +0.26 +0.54%
After hours · Nov 2, 7:35 PM ET
48.25 Day range 52.28
24.60 52-week range 58.83
- YTD
- +66.69%
- 1 year
- +55.12%
- Open
- 52.00
- Prev close
- 51.40
- Mkt cap
- 1.79B
- Vol
- 6.16M
- Avg vol
- 4.66M
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 48.25
- High
- 52.28
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 39.68
- 200-d avg
- 32.15
5Y chart
Events in this range
- Dec 29, 2021Dividend: 0.382
Signals (122)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 2026 | 1 day ago |
| SMA: Bullish | Oct 26, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 19, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 12, 2026 | 3 weeks ago |
| RSI: Overbought | Sep 14, 2026 | 1 month ago |
| RSI: Overbought | Aug 17, 2026 | 2 months ago |
| RSI: Overbought | Jun 22, 2026 | 4 months ago |
| SMA: Bullish | May 18, 2026 | 5 months ago |
| SMA: Bearish | May 11, 2026 | 5 months ago |
| MACD: Buy Signal | Apr 27, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| SMA: Bearish | Mar 2, 2026 | 8 months ago |
| SMA: Bullish | Feb 16, 2026 | 8 months ago |
| SMA: Bearish | Feb 9, 2026 | 8 months ago |
| SMA: Bearish | Jan 26, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 26, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 19, 2026 | 9 months ago |
| SMA: Bullish | Jan 5, 2026 | 10 months ago |
| MACD: Sell Signal | Dec 22, 2025 | 10 months ago |
Newest 20 of 122.
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 39.68
- 200-day average
- 32.15
About ARK Genomic Revolution ETF
The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.
News
- ARKG: Revolutionary Science, Unremarkable Returns
- Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up
- Donald Trump, Cathie Wood Bet on the Same 32 Stocks – Some Might Surprise You
- Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets
- Why Is Tempus AI Stock Falling Friday?
- Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
- What’s Going On With Tempus AI Stock on Monday?
- Merck, Moderna Cancer Vaccine Breakthrough Could Be Catalyst the mRNA ETF Trade Has Been Waiting For
- Cathie Wood Swaps Robinhood for SpaceX, Archer—Did ARK Pivot Back to Moonshot Innovation?
- Tempus AI Slides as Investors Weigh $1.5 Billion Personalis Acquisition
Your note
Sign in to keep a note on ARKG — it syncs with the Stock Master app.
